HOME >> BIOLOGY >> NEWS
Sitagliptin, a new investigational treatment for type 2 diabetes, may offer new hope for patients

There are currently more than 194 million people with diabetes worldwide and this figure could exceed 333 million by 2025 if untreated. [2] Current treatments for type 2 diabetes are often limited by their side effect profile, route of administration or difficulties in sustaining glucose control. [3] As a result, there is a need for better tolerated treatments that do not cause weight gain and produce less risk of hypoglycaemia for patients with type 2 diabetes. The results of the two Phase II studies indicate that sitagliptin, an investigational diabetes drug, appears to control blood sugar with a low incidence of hypoglycaemia and with a neutral effect on body weight.

In the Phase II studies of more than 1,000 patients, ''sitagliptin'', Merck Sharp & Dohme's investigational medicine from a new class of diabetes treatments called dipeptidyl peptidase 4 (DPP-4) inhibitors, improved glycaemic control in patients with type 2 diabetes and exhibited a safety and tolerability profile similar to placebo. In addition, patients taking sitagliptin experienced no significant weight gain and a low risk of hypoglycaemia.

"Results from the studies conducted to date are very promising," said Peter Stein, Senior Director in Clinical Research, Metabolism, Merck Research Laboratories, Rahway, NJ, USA. "The need for well tolerated therapies which achieve better glycaemic control than current therapies is well known and we are confident that these short-term clinical studies demonstrate proof of concept for sitagliptin, offering a new hope for type 2 diabetes patients. Ongoing Phase III trials should provide greater insight into the efficacy and tolerability profile of sitagliptin over a longer period of time".

Study 1: Effect of sitagliptin oral tablets on glycaemic control
Results from a 12-week, double-blind, placebo-controlled, parallel group study in patients with type 2 diabetes showed that sitagliptin oral tablets significantly r
'"/>

Contact: Catherine Pannell
cpannell@hillandknowlton.com
44-207-413-3059
Merck & Co., Inc.
14-Sep-2005


Page: 1 2 3

Related biology news :

1. FUZEON with investigational HIV drug results in remarkable number of patients achieving undetectable
2. Providence health system shows investigational osteoporosis therapy increases bone mineral density
3. Amgen investigational therapy, AMG 162, increased bone mineral density with twice yearly injection
4. New system of wastewater treatment could reduce the size of treatment plants by half
5. UCF research links proteins, stem cells and potential Alzheimers treatment
6. Geisinger scientist seeks cure for Lou Gehrigs disease, creating device to find treatment
7. System to analyze beating heart stem cells could lead to heart attack treatments
8. Gene expression pattern could lead to improved treatment of pediatric septic shock
9. Molecular detectors may refine cancer treatment
10. First genome-wide study of infectious disease opens new avenues for HIV treatment, vaccines
11. A new method of adult stem cell growth efficacious in treatment of disorders of the cornea

Post Your Comments:
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America ... methods for carbon nanotube (CNT) macrostructures, including sheets, yarns ... Dallas (UTD). Leveraging the vast industrial resources ... Tokyo, Japan , Lintec of America is forming ... Richardson, TX , focusing on scaling up the ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
(Date:2/5/2015)... MOUNTAIN VIEW, Calif. , Feb. 3, 2015 ... screen printer technology, demand from industries such as ... the global market for surface mount technology (SMT) ... manual equipment to automatic control will push the ... glue dispensers will remain steady as glue dispensers ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3
(Date:2/26/2015)... Feb. 26, 2015 S&P Capital IQ (MHFI) ... Report coverage on MabVax Therapeutics Holdings Inc . ... clinical stage biotechnology company focused on the development of ... in the treatment of cancer. MabVax has discovered a ... protective immune responses generated by patients who have been ...
(Date:2/26/2015)... TORONTO , Feb. 26, 2015 /PRNewswire/ - SQI ... SQIDF), a life sciences company that develops and commercializes ... reported its financial and operational results for the fiscal ... this press release are in Canadian dollars (CAD), unless ... Company continued to win new business from our existing ...
(Date:2/26/2015)... MENLO PARK, Calif. , Feb. 26, 2015 /PRNewswire/ ... has released the latest version of the Governance ... organizations accomplish governance, risk and compliance (GRC) tasks across ... has also been updated to help customers better align ... Organizations of the Treadway Commission ) requirements. In response ...
(Date:2/26/2015)... Woodbridge, NJ (PRWEB) February 26, 2015 ... and its affiliated companies, Wilentz, Goldman & ... in a trade secrets lawsuit against Genewiz Inc. in ... illegally obtained and utilized GenScript’s trade secrets, and that ... The court entered an order denying motions for ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
Cached News: